CONy 2021 and Headache View overview page

2:21
The evolutionary importance of CGRP
Lawrence Robbins • 23 Sep 2021
1:56
EARLY 2: erenumab in the prevention of high-frequency episodic & chronic migraine in the real world
Piero Barbanti • 27 Sep 2021
1:24
New migraine targets: AMY1 & PACAP
Piero Barbanti • 27 Sep 2021
1:57
CGRP mAbs: adverse effects and clinical trials
Lawrence Robbins • 23 Sep 2021
2:11
Future developments in headache research
Oved Daniel • 24 Sep 2021
1:37
Predictive markers for CGRP-directed antibody treatment success in migraine
Piero Barbanti • 27 Sep 2021
3:32
Is estrogen safe and effective for menstruation-related migraine?
Oved Daniel • 24 Sep 2021
12:05
Lessons on the side effects of CGRP antibodies in migraine
Lawrence Robbins • 23 Sep 2021
4:00
Comparing CGRP ligand- and receptor-directed antibody treatments in migraine
Piero Barbanti • 27 Sep 2021
5:26
Post-traumatic headache: just migraine uncovered by trauma?
Oved Daniel • 24 Sep 2021
1:24
Efficacy and safety of CGRP-directed antibodies in migraine
Lawrence Robbins • 23 Sep 2021
2:52
Is the CGRP ligand or receptor a better target in migraine?
Oved Daniel • 24 Sep 2021
1:31
Evidence supporting estrogen treatment in menstruation-related migraine
Simona Sacco • 17 Sep 2021
1:31
The treatment of menstrually-related migraine & outstanding issues
Simona Sacco • 17 Sep 2021
1:52
Female sex hormones & migraine
Simona Sacco • 17 Sep 2021
4:15
Estrogen treatment for menstruation-related migraine
Simona Sacco • 17 Sep 2021
The content of VJNeurology is intended for healthcare professionals